papers have reported the prevalence of dyslipidemia or metabolic syndrome. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Although LDL-C is a strong predictor of cardiovascular disease and most lipid-lowering drugs are targeted to reduce LDL-C level, there is only limited information about the prevalence and management indexes of high LDL-C in the Korean population. A possible reason for the lack of information on LDL-C level is that common criteria for metabolic syndrome include triglycerides and HDL-C levels but not LDL-C level. 
20)
They also showed that only a small proportion of people with high LDL-C were aware of their condition and were currently under treatment. These estimations inform us about the burden of high LDL-C as well as our current status in preventive therapy for individuals at high cardiovascular risk. This study provides very useful information, especially because it is the first national demonstration of representative data on the prevalence, awareness, and treatment rates of elevated LDL-C. However, we also need to be cautious when we interpret these estimations and compare them with others. Prevalence of a certain disease can be differently estimated for a variety of reasons. Although differences in the study population and study design are the biggest causes of inconsistent prevalence estimation, even studies analyzing the same dataset can produce inconsistent disease prevalence. In addition, the effects of sampling weights can be greater when analyzing subgroup data rather than an entire dataset, because of smaller sample size. Calculation of LDL-C level can be another issue, as the authors already acknowledged. Calculated LDL-C levels are underestimated when compared with directly measured levels, and the discrepancies between two methods vary by sex, age, fasting hours, and triglyceride levels. 24)25) Thus the prevalence, awareness, and treatment rates can be affected by the methods of LDL-C measurement. It is difficult to determine which study produces the best estimate of disease prevalence, because each study involves unique objectives and rationales for the methodologies employed. Instead we should consider the potential causes of different estimates when reporting and interpreting research data on disease prevalence, awareness, and treatment rates. The KNHANES datasets are a useful source for understanding distributions of lipid levels in the Korean population. Direct measurement of LDL-C can be adopted in the KNHANES considering the importance of LDL-C in the diagnosis and treatment of dyslipidemia and the prevention of cardiovascular disease. More studies based on the KNHANES and other population datasets are required to understand where we stand and where we are going in the management of dyslipidemia. Meanwhile, we should be aware of the potential causes of different estimates when we report and compare population data on LDL-C level.
